Sanofi has presented data from two studies demonstrating Lyxumia (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agents (OADs), significantly reduced HbA1c levels...
Category: Products & Tech
Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta(TM), the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited...
Biodel Inc. has partnered with Aegis Therapeutics, LLC (Aegis) and has obtained exclusive worldwide license to Aegis' proprietary ProTek and Intravail technologies for the development and commercialization of pharmaceutical formulations of glucagon...
Tandem announced today, at the 72nd Scientific Sessions of the American Diabetes Association, that it will begin accepting orders for the t:slimTM Insulin Delivery System, the first insulin pump approved by the FDA with a touch screen...
In the next step toward the development of an artificial pancreas, Medtronic announced that it has filed the final module of its Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration for the MiniMed 530G system featuring Threshold Suspend Automation. If approved...
The U.S. FDA has informed Novo Nordisk that a three-month extension period was required in order to complete its regulatory review of the new drug applications (NDA) for the ultra-long-acting insulins degludec and insulin degludec/insulin aspart...
Symphony is a needle free, wireless, transdermal continuous glucose monitoring system designed to provide accurate, real-time continuous blood glucose data...
The European Medicines Agency's (EMA) medicinal committee has recommended the approval of Jentadueto, a type 2 diabetes drug, from Boehringer Ingelheim and Eli Lilly. Jentadueto (linagliptin/metformin hydrochloride) tablets are a medicine combining the DPP-4 inhibitor, linagliptin...
Boehringer Ingelheim and Eli Lilly announced results of a Phase 3 study in African American adults that shows taking Tradjenta (linagliptin) 5mg once-daily tablets sgnificantly reduces hemoglobin A1c (HbA1c)...
The U.S. Food and Drug Administration (FDA) has approved Levemir (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes, making it the first and only basal insulin analog for use in this young patient group. With the expansion of its pediatric indication...